Merck plots 800 job cuts in France, paper says; AZ loses Canadian court ruling on Nexium;

Tools

@FiercePharma: Few drugmakers translate cost cuts into efficiency. Report | Follow @FiercePharma

> Merck plans to cut about 800 jobs in France, or 20 percent of its workforce in the country, following its purchase of Schering-Plough last year, French daily La Tribune reported, citing management and unions. Report

> AstraZeneca's top-selling heartburn and ulcer drug Nexium faces potential generic competition in Canada after a federal court rejected the drugmaker's request to stop a copycat version from being launched in the Canadian market. Report

> Attendees at a small Mylan meeting last September, reportedly the subject of a securities investigation, left the room with little doubt the generic drugmaker was expecting a good quarter, a source who was at the gathering said. Report

> Pfizer's painkiller Celebrex causes less bleeding and fewer ulcers in the gastrointestinal tract than a combination of generic pain pills and heartburn drugs, a company-funded study found. Report

> Pfizer has sued Mylan, accusing the generic drugmaker of infringing patents on its cancer drug Sutent, according to court papers filed Wednesday. Report

> A 2008 lawsuit by U.S. market regulators alleging that three former executives of Biovail made false statements could not yet be decided, a judge ruled. Report

> Shire announced that Dr. David Ginsburg and Anne Minto have been appointed to its board of directors, effective immediately. Release

Biotech News

 @FierceBiotech: Cipla targets $19B biosimilar market with string of new deals. Report | Follow @FierceBiotech

 @JohnCFierce: Here's New York Times' piece on FDA's thoughts on Boehringer's libido drug. Looks like another cruel panel flogging is coming. Report | Follow @JohnCFierce

> Analysts score the FDA expert panels' approval ratings. Story

> Pfizer plans to move fast on rare disease pacts. Report

> Durect's pain drug fails to clear key hurdle in PhIIb. News

> OncoMed scores big cancer development pact with Bayer. Article

Manufacturing News

> Live from DIA: Italy aims for drug-analysis platform. News

> Survey: Costs, reform, compliance are chief supply chain concerns. Story

> MDS: Reactor will restart in July. Report

> Integrators, freight forwarders offer different levels of service. Report

> Pall, Sartorius deals advance disposable bioreactors. Article

Vaccine News

> Swine flu vaccine guards against lethal 1918 virus. Report

> FDA readies new vax safety site. News

> Merck faces new delay at FDA as Gardasil sales slip. Article

> Merck KGaA gets green light on lung cancer vax program. Story

And Finally... Women taking tamoxifen for early-stage breast cancer who developed blood clots were more likely to carry a particular gene mutation than women who did not develop clots. Report